Knight Therapeutics | GUD - Interest Expense On Debt

Stock Price
7.45
Daily Change
0.01 0.13%
Monthly
19.58%
Yearly
22.13%
Q2 Forecast
7.26

Knight Therapeutics reported CAD3.92M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 4.83M 359.32M Dec/2025
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 2.11M 116K Dec/2025
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 7.34M 1.46M Dec/2025
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Ionis Pharmaceuticals USD 18M 0 Dec/2025
IQVIA Holdings USD 193M 4M Dec/2025
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 128M 3M Sep/2025
Revvity USD 23.51M 742K Dec/2025
Tectonic Therapeutic USD 12K 276.99M Dec/2025
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 119.6M 0 Dec/2025
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025